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Abstract
We looked for evidence of antibodies to the 2009 inﬂuenza A/H1N1 pandemic virus in panels of sera from individuals living in metro-
politan France, obtained either before, during or after the epidemic, using standard haemagglutination inhibition and microneutralization
tests. The difference between seroprevalence values measured in post- and pre-epidemic panels was used as an estimate of seroconver-
sion rate in different age groups (23.4% (0–24 years, age-group 0); 16.5% (25–34); 7.9% (35–44); 7.2% (45–54); 1.6% (55–64); and 3.1%
(>65)), conﬁrming that the distribution of cases in different age groups was similar to that of the seasonal H1N1 virus. During the pre-
pandemic period low-titre cross-reactive antibodies were present in a large proportion of the population (presumably acquired against
seasonal H1N1) whereas cross-reactive antibodies were detected in individuals over the age of 65 years with signiﬁcantly higher preva-
lence and serological titres (presumably acquired previously against Spanish ﬂu-related H1N1 strains). Clinical data and analysis of post-
pandemic seroprevalence showed that few of these latter patients were infected by the inﬂuenza virus during the epidemic. In contrast,
the majority of both clinical cases and seroconversions were recorded in the 0–24 age group and a global inverse relationship between
prevalence of antibodies to pH1N1 in the pre-pandemic period and rate of seroconversion was observed amongst age groups. Our
results emphasize the complex relationships involved in antigenic reactivity to pandemic and seasonal H1N1 viral antigens; hence the dif-
ﬁculty in distinguishing between low-titre speciﬁc and cross-reactive antibodies, establishing precise seroprevalence numbers and fully
understanding the relationship between previous immunity to seasonal viruses and protection against the novel variant.
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Introduction
A novel inﬂuenza virus, A/H1N1, emerged in Mexico in April
2009 (pH1N1(2009), referred to here as pH1N1). In June, the
World Health Organization declared a pandemic alert due to
its rapid global dispersal. Signiﬁcant differences between the
antigenic structure of this novel variant and that of H1N1
seasonal viruses (referred to here as sH1N1) that circulated
during the previous decades, were identiﬁed [1–3]. This
agreed with the observed epidemiological dissemination of
the disease that ﬁrst hit western countries during the summer
of 2009 and with the ﬁrst serological studies that appeared to
show limited cross-reactivity between pandemic and seasonal
H1N1 viruses [1,4–10], predicting limited protection following
vaccination based on seasonal inﬂuenza vaccine [5,9].
To date, few seroepidemiological studies of the ﬁrst and
second waves of the 2009 pandemic have been performed
[11–16], but the accumulating data imply that the antigenic
relationship between the pandemic virus and previously
circulating H1N1 viruses is more complex than was initially
realised: antigenic relationships between the haemagglutinin
of the pandemic virus and that of the 1918 H1N1 virus were
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conﬁrmed by structural studies [3,17–21], but a signiﬁcant
correlation was observed between neutralization of
pandemic A/H1N1 and neutralization of a standard seasonal
A/H1N1 strain, and signiﬁcantly higher pH1N1 neutralizing
titres were detected in subjects who had previously received
vaccination against seasonal inﬂuenza in 2008–2009 [22].
Here, we have examined the antibody repertoire of the
pandemic A/H1N1 virus in individuals, using panels of pre-,
per- and post-epidemic sera from French metropolitan popu-
lations. In parallel, we tested pre-pandemic sera for the pres-
ence of antibodies to the recently circulating H1N1 seasonal
virus.
We present the ﬁrst dataset, which allows us to propose
an estimate of the seroconversion rate in the French metro-
politan population during the 2009 pandemic waves and dis-
cuss the distribution of cases in age groups in the light of the
complex antigenic cross-relationships between pandemic and
seasonal H1N1 viral antigens.
Materials and Methods
Ethical issues
This study was approved by the Departmental (IFR48) Ethics
Committee for archival hospital panels and by the ‘Comite´
de Protection des Personnes Ile de France’ for per-pandemic
samples (including patient consent). All information in data-
bases was made anonymous.
Populations studied
Pre-epidemic serum samples. One thousand six hundred and
ninety-three sera collected in 2007–2008 (archival material
randomly selected from the serum library of the Public Hos-
pitals of Marseilles) were tested for antibody to pH1N1,
including a subpopulation of 1020 samples also tested for
sH1N1. The distribution in age groups is indicated in
Table 1.
Post-epidemic samples. Similarly, 1396 archival sera sampled
after the end of the pandemic wave in France (weeks 51-
2009 to 12-2010) were tested for antibody to pH1N1.
Per-epidemic samples. Sera were collected between weeks
45-2009 and 12-2010 from 1541 women (not vaccinated
against pH1N1) tested during the ﬁrst term of pregnancy in
French private biology laboratories (RBML network) for
toxoplasmosis (95% in the 20–39 years age group; median
age, 30). The geographical origin of samples is shown in
Fig. 1. Sera were tested for antibody to pH1N1.
Haemagglutination inhibition (HI) assays
Viral antigen. This was prepared from a phosphate buffer sal-
ine dilution of inﬂuenza virus cell culture supernatant med-
ium, conserved either at )80C (HI-assay) or freeze-dried in
the presence of sucrose 0.2 M (microneutralization assay).
Strains used were: (i) pH1N1: OPYFLU-1, isolated in
Marseille in early May 2009 [8,23], and (ii) sH1N1:
MRS-2007 (closely related to strain A/Paris/6/2007(H1N1)).
HI-assay. This was conducted in a Bio-Safety Level 3 labora-
tory using 5.33 haemagglutinating units of non-inactivated
antigen, serial dilutions (1/10–1/1280) of heat-inactivated
sera, group O human erythrocytes (French Blood Bank), and
Eppendorf epMotion working stations. The HI-titre was
determined as the highest dilution providing clear inhibition
of haemagglutination. All experiments included the same neg-
TABLE 1. Seroprevalence of pandemic H1N1 in pre- and post-epidemic panels, using the haemagglutination inhibition (HI)
method
Pre-epidemic samples (2007–
2008)
Post-epidemic samples
(2010)
Difference (CI) Cases in FMP
Total N = 1693 N¢ = 1396 FMP*
62.8
N¢¢*(CI) Distribution 100%
Age %HI ‡1/40 (CI) %HI ‡1/40 (CI) D ‡1/40 (CI)
P
= 7.5
0–24 383 40.47 (35.55–45.39) 318 63.84 (58.56–69.12) 23.37 (18.09–28.65) 19.4 4.5 (3.5–5.6) 59.8%
25–34 299 43.48 (34.99–51.96) 235 60.00 (50.54–69.46) 16.52 (7.06–25.98) 7.8 1.3 (0.5–2.0) 17.0%
35–44 267 45.32 (33.25–57.38) 231 53.25 (40.25–66.25) 7.93 ()5.07–20.93) 8.9 0.7 (0.0–1.9) 9.3%
45–54 190 51.58 (33.60–69.56) 194 58.76 (41.23–76.29) 7.18 ()10.8–25.16) 8.5 0.6 (0.0–2.1) 8.1%
55–64 205 58.54 (38.03–79.04) 208 60.10 (39.86–80.33) 1.56 ()18.95–22.07) 7.7 0.1 (0.0–1.7) 1.6%
65–100 349 68.77 (51.50–86.03) 210 71.90 (50.32–93.49) 3.14 ()18.45–24.73) 10.5 0.3 (0.0–2.6) 4.3%
The difference between the 2007–2008 baseline and the 2010 seroprevalence was used as an estimate of the seroconversion rate (D ‡1/40).
FMP, French metropolitan population for year 2009 (source INSEE); N, number of samples tested from pre-pandemic panel; N¢, number of samples tested from post-pan-
demic panel; N¢¢, estimates of the number of cases in the French metropolitan population; %HI ‡1/40, proportion of samples with a pH1N1 HI-titre ‡1/40; D ‡1/40, differ-
ence of seroprevalence (titre ‡1/40) between pre- and post-pandemic panels. CI, 95% conﬁdence interval calculated according to the Wald method without continuity
correction.
*Expressed in millions.
Distribution: estimate of the distribution of cases in the different age classes of the FMP, based on N¢¢ values.
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ative and positive controls, and a serum agglutinating activity
control.
Microneutralisation assay
The relationship between HI and seroneutralization results
was examined for 446 sera exhibiting various HI-titres.
Microneutralization was performed in a 96-well microplate
format using MDCK cells, two-fold serial dilutions (1/10–1/
1280) of heat-inactivated sera and 4.103 TCID50/ml of strain
OPYFLU-1. Positive and negative controls were included in
each plate. Serum dilution causing 90% inhibition of viral
infection (i.e. IC90-neutralizing titre) was determined by
immunoﬂuorescence (Argene anti-inﬂuenza A 650 assay).
Results
Pre-epidemic samples
HI-titres for 1693 sera sampled in 2007–2008 are provided
in Table 1 and Fig. 2(a), which show that antibodies to
pH1N1 are observed in all age groups, the seroprevalence
increasing from 40.5% in individuals 0–24 years old to nearly
70% in the elderly. Fig. 2(a) illustrates the different distri-
bution of low and high pH1N1 HI-titres according to age
groups: the prevalence of antibodies at low titre (1/40)
increases with age, except in the elderly where it decreases.
By contrast, HI-titres ‡1/80 are much less prevalent, and
more frequent in individuals >65 years old than in younger
age groups (chi-squared test, p 0.01), in agreement with pre-
vious ﬁndings [8,11,12]. Amongst individuals aged >65, the
prevalence of HI-titres ‡1/80 increases constantly with age,
and exceeds 40% in those aged >85.
The situation was markedly different for sH1N1 serology.
High seroprevalence values were observed in all groups with
speciﬁc characteristics: (i) high titres (>40) were frequent in
all age groups (Fig. 2b) and (ii) the lowest values of both
seroprevalence and HI-titres were observed for individuals
45–54 years old. Individuals who were 50 years old at the
time of our study were 0–20 years old in the 1957–1977
period characterized by the absence of H1N1 viruses circu-
lating in Europe. The serological pattern observed in this age
group may be related to the ‘antigenic sin’, which possibly
coloured all subsequent responses to inﬂuenza [21,24,25].
Post-epidemic samples
One thousand three hundred and ninety-six samples col-
lected in 2010 were tested for the presence of antibody to
pH1N1 and the difference between seroprevalence values
measured in post- and pre-epidemic panels was used as an
estimate of seroconversion rate in different age groups, using
a threshold titre at 1/40 (Table 1): (i) the highest seropreva-
lence increase was observed in individuals <25 years old and
it was low in individuals >55 years old; (ii) a global inverse
relationship between pH1N1 seroprevalence in the pre-pan-
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FIG. 1. Distribution of samples collected from pregnant women
according to the French Defence Zones.
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FIG. 2. Results of haemagglutination inhibition (HI) assays amongst
pre-pandemic sera according to age groups. (a) HI assay using pan-
demic H1N1 antigen (n = 1693). (b) HI assay using seasonal H1N1
antigen (n = 1020).
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demic period and rate of seroconversion was observed
amongst age groups (Fig. 3).
The comparison of pre- and post-epidemic periods
(Fig. 3c) shows that the prevalence of titres £1/20 decreased,
and that of titres ‡1/80 increased. The prevalence of the
1/40 titre decreased in most age groups. A plausible inter-
pretation is that a large proportion of the patients who were
infected reached high antibody titres after the pandemic,
including individuals with a 1/40 pre-epidemic HI-titre. This
implies that a proportion of those with 1/40 pre-epidemic
HI-titre were not efﬁciently protected against infection.
The distribution of cases in age groups was in line with
results previously obtained from biologically conﬁrmed
pH1N1 infections in the region of Marseille [8]. A rough
evaluation of the distribution of cases in the French metro-
politan population, extrapolated from the results of our sam-
ples, suggests that more than 50% of cases occurred in
individuals younger than 25 (Table 1), and that the global
attack rate was in the order of magnitude of 12%.
Interpretation of HI-assay
In a sample of 446 sera, we performed seroneutralization
analysis. The number of positive (titre >1/10, which may be
associated with protective seroneutralizing activity [26]) and
negative microneutralization results was reported for each
HI-titre (Fig. 4). A standard threshold set-up at 1/40 was
associated with high sensitivity and negative predictive values
(90% and 79%, respectively) but poor positive predictive
and speciﬁcity values (85% and 72%, respectively) for the
detection of seroneutralizing antibodies (Fig. 4). A cut-off
value at 1/80 for the HI-assay resulted in giving clear priority
to speciﬁcity (>96%) and positive predictive value (>97%) of
antibody detection over sensitivity (68%) and negative pre-
dictive value (62%). This indicates that titre at 1/80 may rep-
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FIG. 3. Evolution of pH1N1 seroprevalence in pre- and post-pandemic panels according to age groups and haemagglutination inhibition (HI)
titre. (a) pH1N1 seroprevalence in pre-pandemic panel. (b) Estimates of seroconversion rates. (c) Evolution of pH1N1 seroprevalence between
pre- and post-pandemic panels according to HI-titre.
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FIG. 4. Relationship between haemagglutination inhibition (HI) and
microneutralization (MN) titre tested with pandemic H1N1.
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resent a relevant threshold for the speciﬁc diagnosis of
recent pH1N1 infections.
Per-epidemic samples
The evolution of pH1N1 seroprevalence in 1541 non-vacci-
nated pregnant women is shown in Fig. 5, together with the
sequence of inﬂuenza-like illnesses during the period, which
included a peak of rhinovirus infections just before the inﬂu-
enza epidemic peak. It was evaluated over six time-intervals
with comparable enrollment. In the absence of a signiﬁcant
serological baseline in this speciﬁc epidemiological group, the
threshold titre providing the highest positive predictive value
(1/80) was used to detect recent cases. The pH1N1 seropre-
valence rapidly increased (following at a 2.5-week interval
the curve of conﬁrmed pH1N1 infections), peaked at weeks
50–51 and slightly decreased afterwards.
The ﬁrst seroprevalence value was obtained at week 45
(3.9%) and provides a picture of the proportion of individuals
infected at week 42 (considering a 2.5-week interval for
seroconversion). It may slightly overestimate the actual sero-
prevalence baseline, because approximately 14% of con-
ﬁrmed cases were observed before week 42 in the 20–39
years age group according to hospital numbers. A corrected
baseline value (according to the number of cases recorded at
week 42) could be evaluated around 2.4%. Accordingly, the
difference between seroprevalence at the peak (10.5%) or
in the post-epidemic period (8.5%) and the corrected base-
line value was estimated to be around 8.1% and 6.1%,
respectively.
Discussion
We present here the ﬁrst pH1N1 serological study in the
French metropolitan population that allows us to propose an
estimate of seroconversion rates during the 2009 pandemic
waves. The panels studied (patients hospitalized in the public
hospitals of Marseilles) cannot be considered to be represen-
tative of the French metropolitan population but provided
relevant information regarding the distribution of cases in
age groups and its possible mechanisms.
Our study conﬁrms that a large proportion of the popula-
tion tested in the pre-pandemic period had antibodies cross-
reacting with the new virus (up to approximately 70% in the
elderly). In addition, a global inverse relationship between
prevalence of antibodies to pH1N1 in the pre-pandemic per-
iod and estimates of seroconversion was observed amongst
age groups. However, this relationship deserves careful inter-
pretation because the distribution of high-titre antibodies is
very different according to age groups in the pre-epidemic per-
iod. For example, in individuals <25 years old, the presence of
antibodies in more than 40% of individuals was associated with
a low prevalence of high-titre HI antibodies (only 8.6% of indi-
viduals in this group had pH1N1 HI-titres ‡1/80 before the
pandemic) and with limited level of protection (the estimates
of seroconversion rate are over 20% in this age group).
Because (i) there is considerable epidemiological evidence that
this speciﬁc population had no opportunity for previous
contact with the pandemic virus or closely related variants and
(ii) the level of vaccine immunisation is low in this group (<7%,
Groupe d’Expertise et d’Information sur la Grippe, GEIG,
source), it is likely that antibodies to pH1N1 are cross-reacting
antibodies, previously acquired following seasonal inﬂuenza
infection. In support of this hypothesis, Fig. 2(b) shows that
such antibodies are frequent in this age group, and frequently
with high HI-titres. However, this cross-reactivity was mostly
associated with low-titre (1/40) antibodies to pH1N1, which
appear to be associated with signiﬁcant seroneutralizing titres
in a limited proportion of cases (Fig. 4).
With different numbers, this observation globally stands for
individuals in the 25–54 years old age groups, but not for the
elderly. In individuals older than 54 years, the prevalence of
antibodies to pH1N1 was high in the pre-epidemic period, but
most importantly, the prevalence of high-titre antibodies was
much higher than in other age groups (Fig. 3a) and seems to
15%
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 infections
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FIG. 5. Evaluation of pandemic H1N1 seroprevalence in French
metropolitan pregnant women (n = 1541). (a) Sequences of inﬂu-
enza-like illness (ILI), conﬁrmed rhinovirus infections and conﬁrmed
pandemic H1N1 are shown using an arbitrary scale. (b) Grey rectan-
gular areas show the evolution of pandemic H1N1 haemagglutination
inhibition (HI) seroprevalence.
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have been associated with a signiﬁcant level of protection,
considering both seroconversion estimates and epidemiologi-
cal data (numbering of clinical cases) collected in metropolitan
France [23]. This hypothesis is further supported by the fact
that, in our study, HI-titres ‡1/80 were strongly associated
with signiﬁcant seroneutralization titres (Fig. 4). Indeed, in a
previous study, Chen and collaborators observed that, in a
group of subjects with conﬁrmed pH1N1, none had neutraliz-
ing antibodies at titres >10 before the infection [26].
A possible explanation for the efﬁcient protection
observed in the elderly may be iterative vaccination against
seasonal inﬂuenza, because this age group beneﬁts from the
highest vaccine coverage in France (25% (55–59), 35% (60–
64) and around 70% in the >65 age group; GEIG source).
Antibodies to sH1N1 are frequent in this group but this level
and the proportion of individuals with high-titre antibodies is
not markedly different from the youngest age groups.
Another plausible explanation is that these individuals may
have had past exposure to H1N1 variants that share more
antigenic similarity with the novel pandemic variant than
recent sH1N1 strains. An important antigenic drift of H1N1
viruses occurred at the end of the 1940s, and patients over
the age of 60 had the opportunity to be in contact with
‘pre-drift’ viruses (Spanish ﬂu-related H1N1 strains)
[3,7,11,12,27]. Because antigenic relatedness between the
2009 pH1N1 and the 1918 virus has been reported [3,18],
this original immunisation may explain the paucity of infec-
tions reported in this age group in Mexico, the United
States, Australia and other regions of the world where
serological and epidemiological data could be evaluated [24].
Despite the aforementioned reservations regarding the
representativeness of the populations examined, our study
demonstrates that the HI method provides, in the case of
pH1N1, results in line with those obtained by compiling clini-
cal data [7,8,23]. Distribution in age groups is similar in our se-
roprevalence series and in biologically conﬁrmed pH1N1
cases, demonstrating: (i) that the global attack rate was in the
order of magnitude of 12% in the French metropolitan popula-
tion; (ii) that the very ﬁrst target of the pandemic wave was
the population under the age of 25 (the estimated serocon-
version rate reached approximately 24% in the 0–24 age
group and, according to the French metropolitan pyramid of
ages, this means that more than one half of cases presumably
occurred in individuals younger than 25); and (iii) that the
number of cases in individuals older than 54 years was limited.
This distribution of cases is similar to that previously observed
for sH1N1 infections and is different to that of seasonal H3N2
infections, which arecharacterized by a larger proportion of
cases occurring in patients older than 60 years [28].
In addition, the follow-up of a population of pregnant
women tested during the ﬁrst term of pregnancy showed
that, during the winter 2009 pH1N1 outbreak, the increase
of seroprevalence followed that of conﬁrmed cases in the
general population. It also revealed that the seroprevalence
peaked a few weeks after the peak of conﬁrmed cases and
then stabilized at a lower post-pandemic level. This suggests
that a number of individuals who had contact with the pan-
demic virus may have displayed an antibody response detect-
able by HI, but subsequently reverted to undetectable
antibody levels, in agreement with previous studies of natural
or vaccinal immunisation [26,29,30]. This implies that post-
pandemic serological studies may underestimate the actual
number of cases. A similar phenomenon was recently
observed during the prospective follow-up of a household
cohort in Reunion Island (Dellagi et al. submitted data).
The global picture drawn at the end of this study is evoca-
tive of that of a classical seasonal H1N1 outbreak. In particu-
lar, the low number of cases observed in the elderly may
explain the limited over-mortality observed in metropolitan
France following the 2009 inﬂuenza outbreak. This should
not ignore the issue of severe clinical presentations in young
and middle-age individuals observed during the 2009 epi-
demic (which constitute an important difference between
this epidemic and the classical epidemiology of seasonal
H1N1 inﬂuenza) and the need for further identiﬁcation of
the underlying risk factors.
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